Skip to content

Lung squamous cell carcinoma — epidemiology and smoking

TL;DR — An estimated 616,769 squamous-cell lung cancers occurred worldwide in 2022: 461,171 in men and 155,598 in women, representing 29.4% and 17.1% of all lung cancers in those groups (Luo 2025, PMID 39914442). LUSC is the lung-cancer histology most steeply linked to cumulative cigarette exposure: in a pooled analysis of 13,169 cases and 16,010 controls, men smoking more than 30 cigarettes/day had an odds ratio (OR) of 103.5 versus never-smokers; the corresponding OR in women was 62.7 (Pesch 2012, PMID 22052329). Incidence has fallen in many high-income populations as smoking declined, while classification changes have complicated recent trend estimates (Meza 2015, PMID 25822850). Tobacco is dominant but not exclusive: residential radon, asbestos, occupational carcinogens, and ambient pollution contribute, with subtype-specific estimates less secure than for smoking (Li 2020, PMID 32102460; Olsson 2017, PMID 28141674; Zou 2022, PMID 39036545). Smoking cessation remains relevant after diagnosis: quitting at or around diagnosis was associated with lower all-cause mortality in NSCLC (summary relative risk 0.77, 95% CI 0.66–0.90), although the underlying evidence is observational (Caini 2022, PMID 34995798).

Global burden by histology

The most useful current numerator is incidence, not LUSC-specific mortality: death certificates and global registries generally record lung cancer rather than a histologic subtype. A live PubMed search on 2026-08-30 retrieved histology-specific incidence models but no direct global LUSC death-registration estimate. A 2022 incidence model combined GLOBOCAN totals with registry-derived subtype proportions and reassigned unspecified morphology; its estimates therefore depend on pathology coverage and redistribution assumptions (Luo 2025, PMID 39914442).

Population, year LUSC cases Share of all lung cancers Age-standardized rate Method Source
Worldwide men, 2022 461,171 29.4% Not reported as one global value in abstract GLOBOCAN totals × registry subtype fractions Luo 2025, PMID 39914442
Worldwide women, 2022 155,598 17.1% Not reported as one global value in abstract Same model Luo 2025, PMID 39914442
Worldwide men, 2020 351,807 25% 7.7/100,000 person-years GLOBOCAN 2020 × registry subtype fractions Zhang 2023, PMID 37837979
Worldwide women, 2020 91,070 12% 1.6/100,000 person-years Same model Zhang 2023, PMID 37837979
Eastern Europe men, 2022 — — 21.70/100,000 (95% CI 21.51–21.89) Regional modeled estimate Luo 2025, PMID 39914442
North America women, 2022 — — 5.28/100,000 (95% CI 5.21–5.35) Regional modeled estimate Luo 2025, PMID 39914442

The apparent increase from 442,877 modeled cases in 2020 to 616,769 in 2022 should not be read as a two-year biological surge. The studies used different registry volumes, time points, and redistribution procedures; they are displayed separately because averaging them would conceal model dependence (Zhang 2023, PMID 37837979; Luo 2025, PMID 39914442).

Adenocarcinoma exceeded LUSC incidence in 150 of 185 countries among men and all 185 among women in 2020, formalizing the global shift away from the former squamous predominance (Zhang 2023, PMID 37837979). The 2022 analysis nevertheless found substantial residual geographic heterogeneity, especially the high male LUSC rate in eastern Europe (Luo 2025, PMID 39914442).

Tobacco dose–response

The smoking association differs quantitatively by histology. The International Lung Cancer Consortium pooled 13,169 lung-cancer cases and 16,010 controls from Europe and Canada; LUSC predominated in male smokers, whereas adenocarcinoma was the most common subtype in never-smokers and women (Pesch 2012, PMID 22052329).

Exposure contrast LUSC estimate Adenocarcinoma comparator Population/source
Current men, >30 cigarettes/day vs never OR 103.5 (95% CI 74.8–143.2) OR 21.9 (16.6–29.0) 13,169 cases/16,010 controls; Pesch 2012, PMID 22052329
Current women, >30 cigarettes/day vs never OR 62.7 (31.5–124.6) OR 16.8 (9.2–30.6) Same pooled analysis; Pesch 2012, PMID 22052329
Heaviest intensity, across older studies Stronger for squamous/small-cell than adenocarcinoma Adenocarcinoma OR 4.10 (3.16–5.31) 48-study meta-analysis; Khuder 2001, PMID 11165392
Longest duration (≥40 years), across older studies Stronger for squamous/small-cell Adenocarcinoma OR 3.80 (2.35–6.16) 48-study meta-analysis; Khuder 2001, PMID 11165392

Odds ratios above 100 should be interpreted in context: they compare extreme current exposure with never-smoking in case-control data and are not absolute risks. Nevertheless, the much steeper gradient for LUSC than adenocarcinoma is consistent across pooled and meta-analytic designs (Khuder 2001, PMID 11165392; Pesch 2012, PMID 22052329).

Risk begins to decline after cessation but remained above never-smoker baseline even 35 years after quitting in the pooled analysis (Pesch 2012, PMID 22052329). A 27-study meta-analysis similarly found the largest cessation-associated risk reductions for squamous and small-cell histologies, especially among heavy smokers (Khuder 2001, PMID 11713137).

The decreasing LUSC share in the United States is consistent with tobacco control, but pathology coding also matters. SEER data from 1973–2010 showed declining squamous incidence across sex/race groups; an apparent post-2005 increase coincided with fewer tumors classified as “other NSCLC,” suggesting reclassification rather than a clean reversal (Meza 2015, PMID 25822850).

Sex, race, geography, and social patterning

Observation Quantitative or design anchor Interpretation
Male predominance worldwide 2022 modeled cases: 461,171 men vs 155,598 women Reflects historical smoking patterns plus region-specific exposure; Luo 2025, PMID 39914442
Global sex difference in 2020 ASR 7.7/100,000 men vs 1.6/100,000 women A nearly fivefold rate ratio from modeled registry data; Zhang 2023, PMID 37837979
US Black men Disproportionately affected by squamous cancers in SEER 1973–2010 Incidence and later-stage disparities coexist; Meza 2015, PMID 25822850
Asian-American subgroups Histology-specific trends differed across Asian-American, Native Hawaiian, and Pacific Islander groups Aggregating heterogeneous populations can conceal variation; Cheng 2014, PMID 25368400
Taiwan Spatial and temporal incidence differed for adenocarcinoma and squamous carcinoma Local smoking, pollution, and diagnostic patterns are plausible contributors but not separated causally; Liu 2023, PMID 36717588
Catalonia Forecasts through 2025 varied by age, sex, and histology National declines should not be generalized to every demographic stratum; Guarga 2021, PMID 34857781

Sex is not a biological substitute for exposure. An older Spanish population study found five-year relative survival of 11.8% in women and 9.2% in men across lung cancers, but within squamous carcinoma the time-varying relative excess risk did not reproduce the overall female advantage consistently (Salmerón 2012, PMID 22749756).

International incidence follows smoking epidemics with long latency. High-income countries are generally further into the declining phase for male squamous cancer, whereas countries with later tobacco uptake may not be (Cheng 2016, PMID 27364315). Differences in registry completeness, histologic verification, and the size of the “unspecified” category limit cross-country comparisons (Zhang 2023, PMID 37837979; Luo 2025, PMID 39914442).

Non-tobacco exposures

Smoking does not make other carcinogens irrelevant. The correct causal model is often joint exposure rather than mutually exclusive causes (Zou 2022, PMID 39036545).

Exposure Best quantitative anchor LUSC-specific inference Source
Residential radon Highest vs lowest exposure: lung-cancer OR 1.48 (95% CI 1.26–1.73); LUSC OR 1.43 (1.18–1.74) Association present but weaker than for small-cell in this meta-analysis Li 2020, PMID 32102460
Asbestos Ever-exposed men: lung-cancer OR 1.24 (1.18–1.31); rising risk across major subtypes Smoking and asbestos were more than additive in women and approximately multiplicative in men Olsson 2017, PMID 28141674
Uranium-mining radon Histology-specific risk modified by radon exposure, silicosis, or inflammatory genotype across miner cohorts Generalizability to residential exposure is limited Taeger 2006, PMID 16411224; Leng 2016, PMID 26372664
Diesel, silica, metals, welding fumes Established or probable occupational lung carcinogens Most studies estimate lung cancer overall; precise LUSC attributable fractions remain uncertain Zou 2022, PMID 39036545; Siew 2008, PMID 19137206
Ambient air pollution Lung-cancer risk and survival associations documented Contemporary global subtype attribution was modeled for adenocarcinoma, not LUSC Liaw 2008, PMID 18346778; Eckel 2016, PMID 27491839; Luo 2025, PMID 39914442

The radon meta-analysis included 28 case-control studies, 13,748 cases, and 23,112 controls; its subtype result supports an association but cannot eliminate exposure measurement error or residual smoking confounding (Li 2020, PMID 32102460). The asbestos pooled analysis included 17,705 cases and 21,813 controls and used a quantitative job-exposure matrix, giving stronger exposure reconstruction than a simple ever/never occupational history (Olsson 2017, PMID 28141674).

Comorbidity and screening eligibility

The same tobacco exposure that causes LUSC also produces chronic obstructive pulmonary disease, cardiovascular disease, and competing mortality. This matters because incidence, screening benefit, operability, and treatment tolerance are not separable in this population (Molina 2008, PMID 18452692).

In a post-hoc model using 34,690 PLCO and 53,452 NLST participants, LDCT reduced lung-cancer mortality in intermediate comorbidity quintiles but not the highest quintile (cause-specific HR 0.99, 95% CI 0.79–1.23). The highest-comorbidity group had more squamous cancers, more untreated disease, and higher lethality despite localized diagnosis (Gendarme 2025, PMID 39798695). This finding is observational within randomized trials and should be tested prospectively before excluding high-comorbidity individuals.

The foundational NLST randomized 53,454 high-risk participants and found a 20.0% relative reduction in lung-cancer mortality with LDCT versus chest radiography (Aberle 2011, PMID 21714641). NELSON independently showed reduced lung-cancer mortality with volume CT screening (de Koning 2020, PMID 31995683). Neither trial was designed around a LUSC-specific mortality endpoint; histology-specific detection is addressed in screening and early detection.

Smoking cessation after diagnosis

Evidence set Outcome Estimate Important limitation
21 studies, >10,000 lung-cancer patients Overall survival, all histologies Summary RR 0.71 (95% CI 0.64–0.80) for quitting around diagnosis Observational exposure; heterogeneous cessation definitions
NSCLC subset, 8 studies Overall survival Summary RR 0.77 (0.66–0.90) Not LUSC-specific
Early-stage NSCLC review All-cause mortality with continued smoking HR 2.94 (1.15–7.54) Small observational evidence base
Early-stage NSCLC review Recurrence with continued smoking HR 1.86 (1.01–3.41) Residual confounding likely

The survival association is clinically large but not randomized evidence. Quitters may differ in performance status, treatment adherence, socioeconomic resources, or tumor biology. Still, directionally consistent associations across NSCLC and small-cell cohorts make cessation support part of cancer care rather than merely primary prevention (Parsons 2010, PMID 20093278; Caini 2022, PMID 34995798).

Measurement and interpretation cautions

  • Incidence is modeled. Global subtype totals reallocate unspecified morphology; uncertainty is not fully represented by case-count precision (Zhang 2023, PMID 37837979; Luo 2025, PMID 39914442).
  • Mortality is rarely histology-coded. Statements such as “LUSC deaths worldwide” are commonly extrapolations from incidence and survival, not direct registration; the 2022 incidence estimate should therefore replace the seeded mortality shorthand (Luo 2025, PMID 39914442).
  • Coding changes mimic trends. Declining NSCLC-NOS can create apparent increases in named histologies without a biological incidence increase (Meza 2015, PMID 25822850).
  • Smoking measures are imperfect. Current/former status discards duration, intensity, time since quitting, product type, and secondhand exposure; pack-years also compress different histories into one number (Pesch 2012, PMID 22052329).
  • Competing risk is central. Heavy-smoking cohorts have high non-cancer mortality, which changes screening and treatment benefit even when cancer risk is high (Gendarme 2025, PMID 39798695).

Denominators that should not be mixed

Measure Numerator/denominator Best use Main failure mode
Histology share LUSC / all registered lung cancers Describes case mix Changes when NSCLC-NOS classification changes; Meza 2015, PMID 25822850
Crude incidence New LUSC / resident population Local service planning Confounded by population age structure; Luo 2025, PMID 39914442
Age-standardized incidence Weighted age-specific LUSC rates Between-population comparison Depends on standard population and modeled histology; Zhang 2023, PMID 37837979
Case survival Survivors / diagnosed LUSC cases Prognosis after diagnosis Stage, treatment, lead time, and competing death alter comparisons; Salmerón 2012, PMID 22749756
Screening mortality ratio Lung-cancer deaths in screened vs control arm Causal screening effect Not a LUSC-specific endpoint in NLST or NELSON; Aberle 2011, PMID 21714641; de Koning 2020, PMID 31995683

Open questions

  • How much of the 2020-to-2022 modeled increase in global LUSC cases reflects registry coverage and morphology redistribution rather than population growth or changing risk (Zhang 2023, PMID 37837979; Luo 2025, PMID 39914442)?
  • Can screening selection jointly optimize LUSC risk and competing mortality, given absent mortality benefit in the highest-comorbidity NLST quintile (Gendarme 2025, PMID 39798695)?
  • What proportion of contemporary LUSC is attributable to combined tobacco–occupational–radon exposure, using individual-level quantitative exposure rather than one-factor models (Olsson 2017, PMID 28141674; Li 2020, PMID 32102460)?
  • Are declining LUSC rates equitable across race, sex, geography, and socioeconomic strata after correcting for changing histologic classification (Meza 2015, PMID 25822850; Luo 2025, PMID 39914442)?
  • Does structured cessation treatment improve cancer-specific outcomes in a pragmatic trial, or is the observed survival advantage entirely or partly confounded (Parsons 2010, PMID 20093278; Caini 2022, PMID 34995798)?

References

  1. Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348-363. PMID 39914442
  2. Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206-1218. PMID 37837979
  3. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015;10(3):e0121323. PMID 25822850
  4. Cheng I, Le GM, Noone AM, Gali K, Patel M, Haile RW, et al. Lung cancer incidence trends by histology type among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 1990-2010. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2250-65. PMID 25368400
  5. Liu HI, Chiang CJ, Su SY, Jhuang JR, Tsai DR, Yang YW, et al. Incidence trends and spatial distributions of lung adenocarcinoma and squamous cell carcinoma in Taiwan. Sci Rep. 2023;13(1):1655. PMID 36717588
  6. Guarga L, Ameijide A, Marcos-Gragera R, Carulla M, Delgadillo J, Borràs JM, et al. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Sci Rep. 2021;11(1):23274. PMID 34857781
  7. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653-71. PMID 27364315
  8. Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210-9. PMID 22052329
  9. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31(2-3):139-48. PMID 11165392
  10. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120(5):1577-83. PMID 11713137
  11. Morabia A, Wynder EL. Cigarette smoking and lung cancer cell types. Cancer. 1991;68(9):2074-8. PMID 1655236
  12. Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest. 1997;112(6):1474-9. PMID 9404741
  13. Li C, Wang C, Yu J, Fan Y, Liu D, Zhou W, et al. Residential Radon and Histological Types of Lung Cancer: A Meta-Analysis of Case‒Control Studies. Int J Environ Res Public Health. 2020;17(4). PMID 32102460
  14. Olsson AC, Vermeulen R, Schüz J, Kromhout H, Pesch B, Peters S, et al. Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. Epidemiology. 2017;28(2):288-299. PMID 28141674
  15. Taeger D, Fritsch A, Wiethege T, Johnen G, Eisenmenger A, Wesch H, et al. Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners. Cancer. 2006;106(4):881-9. PMID 16411224
  16. Leng S, Thomas CL, Snider AM, Picchi MA, Chen W, Willis DG, et al. Radon Exposure, IL-6 Promoter Variants, and Lung Squamous Cell Carcinoma in Former Uranium Miners. Environ Health Perspect. 2016;124(4):445-51. PMID 26372664
  17. Siew SS, Kauppinen T, Kyyrönen P, Heikkilä P, Pukkala E. Exposure to iron and welding fumes and the risk of lung cancer. Scand J Work Environ Health. 2008;34(6):444-50. PMID 19137206
  18. Zou K, Sun P, Huang H, Zhuo H, Qie R, Xie Y, et al. Etiology of lung cancer: Evidence from epidemiologic studies. J Natl Cancer Cent. 2022;2(4):216-225. PMID 39036545
  19. Liaw YP, Ting TF, Ho KK, Yang CF. Cell type specificity of lung cancer associated with air pollution. Sci Total Environ. 2008;395(1):23-7. PMID 18346778
  20. Eckel SP, Cockburn M, Shu YH, Deng H, Lurmann FW, Liu L, et al. Air pollution affects lung cancer survival. Thorax. 2016;71(10):891-8. PMID 27491839
  21. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94. PMID 18452692
  22. Salmerón D, Chirlaque MD, Isabel Izarzugaza M, Sánchez MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301-8. PMID 22749756
  23. Gendarme S, Irajizad E, Long JP, Fahrmann JF, Dennison JB, Ghasemi SM, et al. Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. J Thorac Oncol. 2025;20(5):565-576. PMID 39798695
  24. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. PMID 21714641
  25. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-513. PMID 31995683
  26. Caini S, Del Riccio M, Vettori V, Scotti V, Martinoli C, Raimondi S, et al. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2022;17(5):623-636. PMID 34995798
  27. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569. PMID 20093278